HELIX BIOMEDIX PEPTIDE STUDIED

Helix BioMedix completed a preliminary study designed to evaluate the efficacy of one the company's proprietary peptides, HB64, in reducing severity of mild to moderate acne symptoms.

Related Videos
Related Content

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022
© 2023 MJH Life Sciences

All rights reserved.